近日，浦江泌尿肿瘤学术大会暨上海市抗癌协会泌尿肿瘤专委会年会在上海举行，国内外泌尿肿瘤领域顶尖专家齐聚一堂，远大医药(00512)在会上重磅发 布"尿路上皮癌早筛早诊项目"，并带来专题报告《尿路上皮癌精准诊疗与泌尿肿瘤核药研发进展》，集中展示公司在早筛早诊、精准诊疗与核药创新的系统 布局与科研实力。 近年来，远大医药持续践行科技创新，已构筑雄厚的创新研发实力及兼具广度与深度的创新布局，并已进入创新业务兑现期，公司"Go Global"创新战略发 展势头正盛。 科技创新铸就核心实力，抗肿瘤产品组合企稳领先地位 在本次浦江泌尿肿瘤学术大会上，远大医药联合多方学术力量，正式发布"四基因联检尿路上皮癌早筛早诊项目"，该项目面向尿路上皮癌诊断、随访、疗效 评估等关键场景，推动无创、便捷、可重复的分子检测进入日常临床路径，其四基因联检拥有基因突变+甲基化双重检测机制、补足传统方法盲区的卓越检 出性能、无创便捷，以及高级别证据导向等技术要点——相关注册临床研究已发布在国际权威期刊《Molecular Cancer》，并成功纳入《中国临床肿瘤学会 (CSCO)尿路上皮癌诊疗指南2024》及《膀胱癌早诊早治专家共识(2024年 ...

科技创新铸就核心实力，抗肿瘤产品组合企稳领先地位 在本次浦江泌尿肿瘤学术大会上，远大医药联合多方学术力量，正式发布"四基因联检尿路上皮癌早筛早诊项目"，该项目面向尿路上皮癌诊断、随访、疗效 评估等关键场景，推动无创、便捷、可重复的分子检测进入日常临床路径，其四基因联检拥有基因突变+甲基化双重检测机制、补足传统方法盲区的卓越检 出性能、无创便捷，以及高级别证据导向等技术要点——相关注册临床研究已发布在国际权威期刊《Molecular Cancer》，并成功纳入《中国临床肿瘤学会 (CSCO)尿路上皮癌诊疗指南2024》及《膀胱癌早诊早治专家共识(2024年版)》，获得国内外专业权威认可。 公司表示，未来将持续深耕分子诊断、精准诊疗与核药研发三大核心领域，并依托全球核药等创新资源与自主研发体系，致力于打造泌尿肿瘤诊疗一体化解 决方案。 智通财经APP获悉，近日，浦江泌尿肿瘤学术大会暨上海市抗癌协会泌尿肿瘤专委会年会在上海举行，国内外泌尿肿瘤领域顶尖专家齐聚一堂，远大医药 (00512)在会上重磅发布"尿路上皮癌早筛早诊项目"，并带来专题报告《尿路上皮癌精准诊疗与泌尿肿瘤核药研发进展》，集中展示公司在早筛早诊、精准 ...

Core Viewpoint - Early diagnosis and intervention in cancer treatment is a primary policy direction in China, as highlighted by the "Healthy China Action - Cancer Prevention and Control Action Implementation Plan (2023-2030)" which emphasizes promoting early diagnosis and treatment of cancer and strengthening screening mechanisms [1] Company Developments - On April 27, 2023, the Hong Kong-listed innovative pharmaceutical company, Yuan Da Pharmaceutical (00512), announced the commercialization of its early detection product, Youai®, for urinary system tumors in collaboration with Beijing Xiangxin Biotechnology Co., Ltd. This product is the only approved dual-mechanism early detection product for urothelial carcinoma in China, marking a significant advancement in non-invasive tumor diagnostics [1][3] - Youai® has received multiple recommendations from authoritative guidelines, including the "2024 CSCO Urothelial Carcinoma Diagnosis and Treatment Guidelines" and the "Bladder Cancer Early Diagnosis and Treatment Expert Consensus (2024 Edition)" [3] - The product demonstrates a sensitivity of 92.5% and specificity of 95.8% based on over 1,000 clinical studies, significantly improving patient comfort compared to invasive procedures like cystoscopy [3] Market Potential - The early detection market for tumors in China is projected to grow significantly, with a compound annual growth rate of 97.9% from 2018 to 2022, reaching approximately 28.5 billion yuan by 2030 [4] - The demand for precise and non-invasive early detection of urinary system tumors is substantial, given the increasing incidence of these cancers, with over 270,000 new cases reported in 2020 [5] Product Pipeline and Innovation - Yuan Da Pharmaceutical is advancing its product pipeline in the nuclear medicine sector, with 15 innovative products under development, covering various radioactive isotopes and multiple cancer types [6][9] - The company has established a comprehensive industrial layout in the nuclear medicine field, including research, production, sales, and regulatory qualifications, aiming to solidify its position as a leader in the global nuclear medicine oncology market [9]